Analysts Set Expectations for LEXX FY2028 Earnings

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Equities researchers at Zacks Research issued their FY2028 earnings per share (EPS) estimates for Lexaria Bioscience in a research report issued to clients and investors on Tuesday, February 10th. Zacks Research analyst J. Vandermosten forecasts that the company will post earnings per share of ($0.28) for the year. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share.

LEXX has been the topic of a number of other reports. Wall Street Zen downgraded shares of Lexaria Bioscience from a “hold” rating to a “sell” rating in a research note on Sunday, December 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lexaria Bioscience in a research report on Monday, December 29th. Finally, HC Wainwright reduced their price target on Lexaria Bioscience from $4.00 to $1.50 and set a “buy” rating for the company in a report on Friday, December 26th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $1.50.

Lexaria Bioscience Price Performance

NASDAQ LEXX opened at $0.64 on Wednesday. The company has a 50 day simple moving average of $0.77 and a 200-day simple moving average of $0.92. The firm has a market capitalization of $15.87 million, a price-to-earnings ratio of -1.14 and a beta of 0.56. Lexaria Bioscience has a 52-week low of $0.46 and a 52-week high of $1.90.

Lexaria Bioscience (NASDAQ:LEXX) last posted its quarterly earnings results on Tuesday, January 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. Lexaria Bioscience had a negative return on equity of 226.58% and a negative net margin of 1,685.84%.The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.14 million.

Institutional Investors Weigh In On Lexaria Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in LEXX. Byrne Asset Management LLC lifted its stake in Lexaria Bioscience by 236.8% in the 4th quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock valued at $65,000 after purchasing an additional 74,180 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Lexaria Bioscience in the 3rd quarter valued at $28,000. Finally, Geode Capital Management LLC lifted its stake in shares of Lexaria Bioscience by 25.7% in the 4th quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock valued at $136,000 after acquiring an additional 44,939 shares during the last quarter. 13.06% of the stock is owned by institutional investors.

About Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.